At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,221 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Patients With Unresectable, Advanced and Recurrent Non-small Cell Lung Cancer or Extensive Disease Small Cell Lung Cancer
In Brief
An observational study for Non-small Cell Lung Cancer and Extensive Disease Small Cell Lung Cancer. Completed, enrolled 1,221 participants across 148 sites.
Detailed Summary
This is a multi-center observational study of atezolizumab combination therapy in patients with unresectable, advanced and recurrent non-small cell lung cancer(NSCLC) or extensive disease small cell lung cancer(ED-SCLC). 800 patients in NSCLC cohort and 400 patients in ED-SCLC cohort will be enrolled in this trial to assess the efficacy and safety of this combination.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesJapan
CollaboratorsJapan Lung Cancer Society
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartAug 2020
Primary CompletionFeb 2023
TodayJul 2026
First PostedAug 6, 2020
Enrollment StartAug 21, 2020
Primary CompletionFeb 3, 2023
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 5.9 years ago